Haploidentical Hematopoietic Stem Cell Transplantation Followed by 'Post-Cyclophosphamide': The Future of Allogeneic Stem Cell Transplant

Overview

Journal Clin Hematol Int

Specialty Hematology

Date 2021 Oct 1

PMID 34595443

Citations 7

Authors

Samuel Cytryn

Maher Abdul-Hay

Affiliations

Soon will be listed here.

Abstract

Allogeneic hematopoietic cell transplant (Allo-HCT) is a potentially curative therapy for many malignant and nonmalignant hematological diseases. However, a suitable human leukocyte antigens (HLAs)-matched donor may not be available when the patient is in urgent need of a stem cell transplant. This challenge has been ameliorated to a large extent by the introduction of haploidentical donors. This type of donor shares one HLA haplotype with the recipient. Therefore, a patient's full sibling has a 50% chance of being haploidentical and a patient's biologic parents and children will all be haploidentical, thus providing an immediately accessible, motivated donor for almost every recipient. Haploidentical transplants previously incurred prohibitively poor outcomes, preventing their widespread use. However, several recent advances have dramatically improved the results, making them a more viable donor source. In this review, we discuss different types of donors used for Allo-HCT with a particular focus on the use of haploidentical donors and their future potential.

Citing Articles

Advances in hematopoietic stem cells ex vivo expansion associated with bone marrow niche.

Deng J, Tan Y, Xu Z, Wang H Ann Hematol. 2024; 103(12):5035-5057.

PMID: 38684510 DOI: 10.1007/s00277-024-05773-1.

Reduced post-transplant cyclophosphamide dose with antithymocyte globulin in peripheral blood stem cell haploidentical transplantation.

Dulery R, Malard F, Brissot E, Banet A, Sestili S, Belhocine R Bone Marrow Transplant. 2023; 58(11):1215-1222.

PMID: 37596473 DOI: 10.1038/s41409-023-02085-2.

Reduced post-transplant cyclophosphamide doses in haploidentical hematopoietic cell transplantation for elderly patients with hematological malignancies.

Dulery R, Goudet C, Mannina D, Bianchessi A, Granata A, Harbi S Bone Marrow Transplant. 2022; 58(4):386-392.

PMID: 36585459 DOI: 10.1038/s41409-022-01908-y.

Should anti-thymocyte globulin be added in post-transplant cyclophosphamide based matched unrelated donor peripheral blood stem cell transplantation for acute myeloid leukemia? A study on behalf of the Acute Leukemia Working Party of the EBMT.

Spyridonidis A, Labopin M, Brissot E, Moiseev I, Cornelissen J, Choi G Bone Marrow Transplant. 2022; 57(12):1774-1780.

PMID: 36071114 DOI: 10.1038/s41409-022-01816-1.

Practicing Clinical Hematology During the COVID-19 Outbreak: A Challenge Like No Other.

Mohty M, Nagler A, Savani B Clin Hematol Int. 2021; 2(2):41-42.

PMID: 34595442 PMC: 8432345. DOI: 10.2991/chi.d.200506.001.

References

Lorentino F, Labopin M, Bernardi M, Ciceri F, Socie G, Cornelissen J . Comparable outcomes of haploidentical, 10/10 and 9/10 unrelated donor transplantation in adverse karyotype AML in first complete remission. Am J Hematol. 2018; 93(10):1236-1244. DOI: 10.1002/ajh.25231. View

Atilla E, Ataca Atilla P, Bozdag S, Demirer T . A review of infectious complications after haploidentical hematopoietic stem cell transplantations. Infection. 2017; 45(4):403-411. DOI: 10.1007/s15010-017-1016-1. View

Kanate A, Szabo A, Raj R, Bower K, Grulke R, Shah N . Comparison of Graft Acquisition and Early Direct Charges of Haploidentical Related Donor Transplantation versus Umbilical Cord Blood Transplantation. Biol Blood Marrow Transplant. 2019; 25(7):1456-1464. DOI: 10.1016/j.bbmt.2019.03.013. View

Crocchiolo R, Castagna L, Furst S, Devillier R, Sarina B, Bramanti S . The patient's CMV serological status affects clinical outcome after T-cell replete haplo-HSCT and post-transplant cyclophosphamide. Bone Marrow Transplant. 2016; 51(8):1134-6. DOI: 10.1038/bmt.2016.69. View

Gorin N, Labopin M, Blaise D, de Groot M, Socie G, Bourhis J . Stem cell transplantation from a haploidentical donor versus a genoidentical sister for adult male patients with acute myelogenous leukemia in first remission: A retrospective study from the acute leukemia working party of the European Society for.... Cancer. 2019; 126(5):1004-1015. DOI: 10.1002/cncr.32629. View

Giannotti F, Labopin M, Shouval R, Sanz J, Arcese W, Angelucci E . Haploidentical transplantation is associated with better overall survival when compared to single cord blood transplantation: an EBMT-Eurocord study of acute leukemia patients conditioned with thiotepa, busulfan, and fludarabine. J Hematol Oncol. 2018; 11(1):110. PMC: 6117895. DOI: 10.1186/s13045-018-0655-8. View

Ruutu T, Gratwohl A, de Witte T, Afanasyev B, Apperley J, Bacigalupo A . Prophylaxis and treatment of GVHD: EBMT-ELN working group recommendations for a standardized practice. Bone Marrow Transplant. 2013; 49(2):168-73. DOI: 10.1038/bmt.2013.107. View

Gu Z, Wang L, Yuan L, Huang W, Li M, Guan L . Similar outcomes after haploidentical transplantation with post-transplant cyclophosphamide versus HLA-matched transplantation: a meta-analysis of case-control studies. Oncotarget. 2017; 8(38):63574-63586. PMC: 5609944. DOI: 10.18632/oncotarget.18862. View

Lee S, Klein J, Haagenson M, Baxter-Lowe L, Confer D, Eapen M . High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood. 2007; 110(13):4576-83. DOI: 10.1182/blood-2007-06-097386. View

10.

Laver J, Hulsey T, Jones J, Gautreaux M, Barredo J, Abboud M . Assessment of barriers to bone marrow donation by unrelated African-American potential donors. Biol Blood Marrow Transplant. 2001; 7(1):45-8. DOI: 10.1053/bbmt.2001.v7.pm11215698. View

11.

Daikeler T, Labopin M, Ruggeri A, Crotta A, Abinun M, Hussein A . New autoimmune diseases after cord blood transplantation: a retrospective study of EUROCORD and the Autoimmune Disease Working Party of the European Group for Blood and Marrow Transplantation. Blood. 2012; 121(6):1059-64. DOI: 10.1182/blood-2012-07-445965. View

12.

Ciurea S, de Lima M, Cano P, Korbling M, Giralt S, Shpall E . High risk of graft failure in patients with anti-HLA antibodies undergoing haploidentical stem-cell transplantation. Transplantation. 2009; 88(8):1019-24. PMC: 4324621. DOI: 10.1097/TP.0b013e3181b9d710. View

13.

Gorin N, Labopin M, Polge E, Cordonnier C, Jouet J, Michallet M . Risk assessment in adult acute lymphoblastic leukaemia before early haemopoietic stem cell transplantation with a geno-identical donor: an easy clinical prognostic score to identify patients who benefit most from allogeneic haemopoietic stem cell.... Leukemia. 2003; 17(8):1596-9. DOI: 10.1038/sj.leu.2403030. View

14.

Myaskovsky L, Switzer G, Dew M, Goycoolea J, Confer D, Abress L . The association of donor center characteristics with attrition from the national marrow donor registry. Transplantation. 2004; 77(6):874-80. DOI: 10.1097/01.tp.0000116394.88804.a7. View

15.

Barker J, Krepski T, DeFor T, Davies S, Wagner J, Weisdorf D . Searching for unrelated donor hematopoietic stem cells: availability and speed of umbilical cord blood versus bone marrow. Biol Blood Marrow Transplant. 2002; 8(5):257-60. DOI: 10.1053/bbmt.2002.v8.pm12064362. View

16.

Lown R, Shaw B . Beating the odds: factors implicated in the speed and availability of unrelated haematopoietic cell donor provision. Bone Marrow Transplant. 2012; 48(2):210-9. DOI: 10.1038/bmt.2012.54. View

17.

Rubinstein P, Carrier C, Scaradavou A, Kurtzberg J, Adamson J, Migliaccio A . Outcomes among 562 recipients of placental-blood transplants from unrelated donors. N Engl J Med. 1998; 339(22):1565-77. DOI: 10.1056/NEJM199811263392201. View

18.

Baker M, Wang H, Rowley S, Cai L, Pecora A, Skarbnik A . Comparative Outcomes after Haploidentical or Unrelated Donor Bone Marrow or Blood Stem Cell Transplantation in Adult Patients with Hematological Malignancies. Biol Blood Marrow Transplant. 2016; 22(11):2047-2055. DOI: 10.1016/j.bbmt.2016.08.003. View

19.

Sun Y, He G, Chang Y, Xu L, Zhang X, Han W . The incidence, risk factors, and outcomes of primary poor graft function after unmanipulated haploidentical stem cell transplantation. Ann Hematol. 2015; 94(10):1699-705. DOI: 10.1007/s00277-015-2440-x. View

20.

Ash R, Horowitz M, Gale R, van Bekkum D, Casper J, Gordon-Smith E . Bone marrow transplantation from related donors other than HLA-identical siblings: effect of T cell depletion. Bone Marrow Transplant. 1991; 7(6):443-52. View